Trial Profile
A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Enclomifene (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Registrational
- Acronyms DEXA
- Sponsors Repros Therapeutics
- 02 Feb 2015 Data from this trial supported an NDA submission to the US FDA for enclomifene in the treatment of secondary hypogonadism in overweight men, according to a Repros Therapeutics media release.
- 21 Oct 2014 An NDA for enclomifene is expected to be filed to the US FDA around the end of 2014, according to a Repros Therapeutics media release.
- 21 Oct 2014 Results published in a Repros Therapeutics media release.